Glucose Health, Inc.
GLUC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GLUC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GLUC
Glucose Health, Inc. (GLUC) is a development-stage company focused on marketing dietary supplement products for diabetes management, with nominal revenues and significant working capital deficits.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2017.
Tracking 2 pipeline candidates for Glucose Health, Inc..
Glucose Health, Inc. (GLUC) is a development-stage company focused on marketing dietary supplement products for diabetes management, with nominal revenues and significant working capital deficits.
- As of September 30, 2017, the company reported cash of $16,636 and total assets of $26,353 [sec_mda · as of 2017-11-14].
- Net income for the nine months ended September 30, 2017 increased compared to the same period in 2016, attributed to higher gross profit and a gain on settlement of an account payable [sec_mda · as of 2017-11-14].
- Current liabilities totaled $452,585 as of September 30, 2017, including convertible notes and accounts payable [sec_mda · as of 2017-11-14].
- The company's auditors have raised a 'going concern' qualification about its ability to continue operations [sec_mda · as of 2016-04-14].
What works
- The company reported increased net income for the nine months ended September 30, 2017 versus the prior year period, driven by higher gross profit and a gain on settlement of an account payable [sec_mda · as of 2017-11-14].
- Glucose Health has launched its Type2 Defense dietary supplement product and is pursuing retail online sales, indicating an active go-to-market strategy [sec_mda · as of 2014-06-25].
What to weigh
- As of September 30, 2017, the company had a working capital deficit with current liabilities ($452,585) far exceeding total assets ($26,353) [sec_mda · as of 2017-11-14].
- The company has a history of nominal revenues and remains in the development stage, with auditors questioning its ability to continue as a going concern [sec_mda · as of 2014-06-25] [sec_mda · as of 2016-04-14].
- The company requires additional capital to continue operations and cannot guarantee that funding will be available on favorable terms [sec_mda · as of 2015-08-18].
From the filings
Quoted directly from source documents.
The company had nominal cash and a working capital deficit as of mid-2015.
“At June 30, 2015 we had nominal cash, which will not be sufficient to satisfy our working capital requirements for the next twelve months.”
SEC MD&A · August 18, 2015
The company remains in the development stage with nominal sales.
“As we only had nominal sales in the twelve months ended December 31, 2013, we have remained in the development stage.”
SEC MD&A · June 25, 2014
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Auditors have questioned the company's ability to continue as a going concern [sec_mda · as of 2016-04-14].
- Working capital deficit — Current liabilities of $452,585 far exceed total assets of $26,353 as of September 30, 2017 [sec_mda · as of 2017-11-14].
- Dependence on additional financing — The company requires additional capital to continue operations and cannot guarantee funding on favorable terms [sec_mda · as of 2015-08-18].
- Development stage with nominal revenues — The company has a history of nominal sales and remains in the development stage [sec_mda · as of 2014-06-25].
What to watch
- Ability to generate sustainable revenues from the Type2 Defense product and other dietary supplements [sec_mda · as of 2014-06-25].
- Success in securing additional capital through public or private financing, borrowings, or from officers and directors [sec_mda · as of 2015-08-18].
- Trend in net income and gross profit, especially given the improvement reported for the nine months ended September 30, 2017 [sec_mda · as of 2017-11-14].
- Any changes in the going concern qualification from auditors in future filings [sec_mda · as of 2016-04-14].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Glucose Health, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Glucose Health, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
34.9 months
OCF -$2K · Net income $19K
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Glucose Health, Inc.?
Glucose Health, Inc. (GLUC) is a development-stage company focused on marketing dietary supplement products for diabetes management, with nominal revenues and significant working capital deficits.
What is Glucose Health, Inc.'s lead drug candidate?
Glucose Health, Inc.'s most advanced tracked candidate is glucose health (Approved) for pre-diabetes and Type-2 diabetes.
Who is the CEO of Glucose Health, Inc.?
Mr. Mark D. Schaftlein is the chief executive officer of Glucose Health, Inc. (GLUC).
Where is Glucose Health, Inc. headquartered?
Glucose Health, Inc. (GLUC) is headquartered in Bentonville, AR, United States.
What therapeutic areas does Glucose Health, Inc. focus on?
Glucose Health, Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.